This report studies the Global Minimally Invasive Hemodynamic Monitoring Devices Market over the
forecast period of 2019 to 2023. The Global Minimally Invasive Hemodynamic Monitoring Devices
Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2019 to 2023.
The Global Minimally Invasive Hemodynamic Monitoring Devices Market research report is the study
prepared by analysts, which contain a detailed analysis of drivers, restraints, and opportunities along
with their impact on the Minimally Invasive Hemodynamic Monitoring Devices Market growth (2019 -
2023).
Different minimally invasive haemodynamic monitoring techniques are commercially available today
and in the recent years they have proved adequate in replacing the pulmonary artery catheter under
certain clinical conditions. Moreover, several of these techniques provide additional new parameters
primarily related to preload assessment. Therefore, in order to be used in daily clinical practice, the
diversity of minimally invasive haemodynamic monitoring requires knowledge of the different
techniques, the different parameters provided by the devices and their clinical validity.
Major Players profiled in the Minimally Invasive Hemodynamic Monitoring Devices Market report
incorporate: Edwards Lifesciences, Philips, ICU Medical, Panasonic, Cheetah Medical, GE, Nihon Kohden,
Draeger, Schwarzer Cardiotek, Getinge (Pulsion), Cnsystems, Mindray, LIDCO, Uscom, Deltex Medical,
Osypka Medical, Baolihao
Top Industry For Minimally Invasive Hemodynamic Monitoring Devices:
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for
structural heart disease and critical care monitoring, announced that the HemoSphere advanced
hemodynamic monitoring platform has received U.S. Food and Drug Administration clearance for the
Acumen suite of intelligent decision-support solutions. The latest HemoSphere platform is the first and
only to include solutions for predictive monitoring of moderate to high-risk surgical patients, which
make up the Acumen suite of intelligent decision-support solution
"Combining the Swan-Ganz catheter and the FloTrac sensor with the Acumen suite and the Hypotension
Prediction Index software on the HemoSphere platform presents a powerful integration of
hemodynamic information," said Neal W. Fleming, M.D., Ph.D., Professor and Director of Cardiovascular
and Thoracic Anesthesia, UC Davis School of Medicine. "The common interface simplifies the workplace
for clinicians while providing comprehensive guidance to optimize and individualize patient care."
The addition of AI technology makes the HemoSphere platform a unique solution for advanced
hemodynamic monitoring. Algorithms that make up the HPI feature are the result of accumulated
experiences from more than 200,000 patient events. Linking pressure and flow parameters with
predictive monitoring in one single platform provides clinicians with the level of decision support
needed to respond proactively based on a patient's needs.